Blood Vessels are Regulators of Growth, Diagnostic Markers and Therapeutic Targets in Prostate Cancer

REFERENCES

• Lekas E, Engstrand C, Bergh A, Damber JE. Transient ischemia induces apoptosis in the ventral prostate of the rat. Urol Res 1999; 27: 174–9.
   PubMedGoogle Scholar
• Lekas E, Johansson M, Widmark A, Bergh A, Damber JE. Decrement of blood flow precedes the involution of the ventral prostate in the rat after castration. Urol Res 1997; 25: 309–14.
   Google Scholar
• Franck-Lissbrant I, Haggstrom S, Damber JE, Bergh A. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology 1998; 139: 451–6.
   Google Scholar
• Folkman J. Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence. Endo-crinology 1998; 139: 441–2.
   PubMed Web of Science ®Google Scholar
• Hayek OR, Shabsigh A, Kaplan SA, Kiss AJ, Chen MW, Burchardt T, et al. Castration induces acute vasoconstriction of blood vessels in the rat prostate concomitant with a reduction of prostatic nitric oxide synthase activity. J Urol 1999; 162: 1527–31.
   PubMed Web of Science ®Google Scholar
• Shabisgh A, Tanji N, D'Agati V, Burchardt M, Rubin M, Goluboff ET, et al. Early effects of castration on the vascular system of the rat ventral prostate gland. Endocrinology 1999; 140: 1920–26.
   Google Scholar
• Shabsigh A, Chang DT, Heitjan DF, Kiss A, Olsson CA, Puchner PJ, et al. Rapid reduction in blood flow to the rat ventral prostate gland after castration: prelimin-ary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival. Prostate 1998; 36: 201–6.
   PubMed Web of Science ®Google Scholar
• Buttyan R, Ghafar MA, Shabsigh A. The effects of androgen deprivation on the prostate gland: cell death mediated by vascular regression. Curr Opin Urol 2000; 10: 415–20.
   Google Scholar
• Shabsigh A, Ghafar MA, de la TA, Burchardt M, Kaplan SA, Anastasiadis AG, et al. Biomarker analysis demonstrates a hypoxic environment in the castrated rat ventral prostate gland. J Cell Biochem 2001; 81: 437–44.
   PubMed Web of Science ®Google Scholar
• JaM RK, Safabakhsh N, Sckell A, Chen Y, Jiang P, Benjamin L, et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci USA 1998; 95: 10820–25.
   PubMed Web of Science ®Google Scholar
• Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Chin Invest 1999; 103: 159–65.
   Google Scholar
• Okihara K, Watanabe H, Kojima M. Kinetic study of tumor blood flow in prostatic cancer using power Doppler imaging. Ultrasound Med Biol 1999; 25: 89–94.
   Google Scholar
• Stewart RJ, Panigrahy D, Flynn E, Folkman J. Vascular endothelial growth factor expression and tumor angio-genesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular en-dothelial growth factor transcripts. J Urol 2001; 165: 688–93.
   PubMed Web of Science ®Google Scholar
• O'Brien TS, Harris AL. Angiogenesis in urological malignancy. Br J Urol 1995; 76: 675–82.
   PubMedGoogle Scholar
• Campbell SC. Advances in angiogenesis research: relevance to urological oncology. J Urol 1997; 158: 1663–74.
   PubMed Web of Science ®Google Scholar
• Jones A, Fujiyama C. Angiogenesis in urological malignancy: prognostic indicator and therapeutic target. BJU Int 1999; 83: 535–55.
   PubMed Web of Science ®Google Scholar
• Bostwick DG, Iczkowski KA. Microvessel density in prostate cancer: prognostic and therapeutic utility. Semin Urol Oncol 1998; 16: 118–23.
   PubMedGoogle Scholar
• Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757–63.
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000; 21: 505–15.
   PubMed Web of Science ®Google Scholar
• Keshet E, Ben Sasson SA. Anticancer drug targets: approaching angiogenesis. J Chin Invest 1999; 104: 1497–501.
   PubMed Web of Science ®Google Scholar
• Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000; 52:237–268.
   PubMed Web of Science ®Google Scholar
• Boehm-Viswanathan T. Why angiogenesis inhibition? Int J Mol Med 1999; 4: 413–17.
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis. In: Bast RC, Kufe DW, Pollock RE, Weichselbaurn RR, Holland JF, Frei EE, editors. Cancer medicine. Hamilton, Ontario: B.C. Decker Inc; 2000: 132–52.
   Google Scholar
• Risau W. Development and differentiation of endothe-lium. Kidney Int Suppl 1998; 67: S3–S6.
   Google Scholar
• Carmeliet P. Mechanisms of angiogenesis and arterio-genesis. Nat Med 2000; 6: 389–95.
   PubMed Web of Science ®Google Scholar
• Rafti S. Circulating endothelial precursors: mystery, reality, and promise. J Chin Invest 2000; 105: 17–19.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial pro-genitor cells for neovascularization. Nat Med 1999; 5: 434–8.
   PubMed Web of Science ®Google Scholar
• Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogen-esis in physiological and pathological neovasculariza-tion. Circ Res 1999; 85: 221–8.
   PubMed Web of Science ®Google Scholar
• Tomanek RJ, Schatteman GC. Angiogenesis: new insights and therapeutic potential. Anat Rec 2000; 261: 126–35.
   PubMedGoogle Scholar
• Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671–4.
   PubMed Web of Science ®Google Scholar
• Pettersson A, Nagy JA, Brown LF, Sundberg C, Morgan E, Jungles S, et al. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endo-thelial growth factor. Lab Invest 2000; 80: 99–115.
   PubMed Web of Science ®Google Scholar
• Dvorak HF. VPFNEGF and the angiogenic response. Semin Perinatol 2000; 24: 75–8.
   PubMed Web of Science ®Google Scholar
• Darland DC, D'Amore PA. Blood vessel maturation: vascular development comes of age. J Clin Invest 1999; 103: 157–8.
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis and angiogenesis inhibition: an overview. EXS 1997; 79: 1–8.
   PubMedGoogle Scholar
• Folkman J. Angiogenesis in cancer, vascular, rheuma-toid and other disease. Nat Med 1995; 1: 27–31.
   PubMed Web of Science ®Google Scholar
• Pepper MS. Lymphangiogenesis and tumor metastasis: myth or reality? Chin Cancer Res 2001; 7: 462–8.
   Web of Science ®Google Scholar
• Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tu-mour metastasis. EMBO J 2001; 20: 672–82.
   PubMed Web of Science ®Google Scholar
• Folkman J, Hanahan D. Switch to the angiogenic phenotype during turnorigenesis. Princess Takamatsu Symp 1991; 22: 339–47.
   PubMedGoogle Scholar
• Hanahan D, Folkman J. Patterns and emerging mech- anisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353–64.
   PubMed Web of Science ®Google Scholar
• Parangi S, O'Reilly M, Christofori G, Holmgren L, Grosfeld J, Folkman J, et al. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 1996; 93: 2002–7.
   PubMed Web of Science ®Google Scholar
• Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression [see comments]. Nat Med 1995; 1: 149–53.
   PubMed Web of Science ®Google Scholar
• Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58: 1408–16.
   PubMed Web of Science ®Google Scholar
• Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999; 18: 5356–62.
   Google Scholar
• Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculo-genic mimicry. Am J Pathol 1999; 155: 739–52.
   Google Scholar
• Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 2000; 97: 14608–13.
   PubMed Web of Science ®Google Scholar
• Tsurusaki T, Kanda S, Sakai H, Kanetake H, Saito Y, Alitalo K, et al. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer 1999; 80: 309–13.
   PubMed Web of Science ®Google Scholar
• Folkman J. Antiangiogenic therapy. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott-Raven Publishers; 1997: 3075–85.
   Google Scholar
• Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 1996; 32A: 2534–9.
   PubMed Web of Science ®Google Scholar
• Fanelli M, Locopo N, Gattuso D, Gasparini G. Assessment of tumor vascularization: immunohisto-chemical and non-invasive methods. Int J Biol Markers 1999; 14: 218–31.
   PubMed Web of Science ®Google Scholar
• Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995; 55: 4575–80.
   PubMed Web of Science ®Google Scholar
• Stellmach V, Volpert OV, Crawford SE, Lawler J, Hynes RO, Bouck N. Tumour suppressor genes and angiogenesis: the role of TP53 in fibroblasts. Eur J Cancer 1996; 32A: 2394–2400.
   PubMed Web of Science ®Google Scholar
• Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999; 56: 794–814.
   PubMed Web of Science ®Google Scholar
• Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999; 77: 527–43.
   PubMed Web of Science ®Google Scholar
• Beckner ME. Factors promoting tumor angiogenesis. Cancer Invest 1999; 17: 594–623.
   PubMed Web of Science ®Google Scholar
• Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular devel-opment. Genes Dev 1999; 13: 1055–66.
   PubMed Web of Science ®Google Scholar
• Sun IC, McClain J, Thurston G, McDonald DM, Zhou H, Oldmixon EH, et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 1998; 282: 468–71.
   PubMed Web of Science ®Google Scholar
• Jaffe RB. Importance of angiogenesis in reproductive physiology. Semin Perinatol 2000; 24: 79–81.
   PubMed Web of Science ®Google Scholar
• Pepper MS. Manipulating angiogenesis. From basic science to the bedside. Arterioscler Thromb Vasc Biol 1997; 17: 605–19.
   PubMed Web of Science ®Google Scholar
• Dickson MC, Martin JS, Cousins FM, Kulkami AB, Karlsson S, Akhurst RJ. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development 1995; 121: 1845–54.
   PubMed Web of Science ®Google Scholar
• Li DY, Sorensen LK, Brooke BS, Umess LD, Davis EC, Taylor DG, et al. Defective angiogenesis in mice lacking endoglin. Science 1999; 284: 1534–7.
   PubMed Web of Science ®Google Scholar
• Desai SB, Libutti SK. Tumor angiogenesis and endothelial cell modulatory factors. J Immunother 1999; 22: 186–211.
   PubMed Web of Science ®Google Scholar
• Norrby K. Angiogenesis: new aspects relating to its initiation and control. APMIS 1997; 105: 417–37.
   PubMed Web of Science ®Google Scholar
• Iruela-Arispe ML, Dvorak HF. Angiogenesis: a dy-namic balance of stimulators and inhibitors. Thromb Haemost 1997; 78: 672–77.
   PubMed Web of Science ®Google Scholar
• Gasparini G. The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs 1999; 58: 17–38.
   PubMed Web of Science ®Google Scholar
• Westphal JR, Ruiter DJ, De Waal R1\4. Anti-angiogenic treatment of human cancer: pitfalls and promises. Int J Cancer 2000; 86: 870–73.
   PubMedGoogle Scholar
• O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2: 689–92.
   PubMed Web of Science ®Google Scholar
• Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404–07.
   Google Scholar
• Weidner N. Tumoral Vacularity: What does it tell us about the growth and spread of cancer. In: Maragou-dakis ME, editor. Angiogenesis: models, modulators, and clinical applications. New York: Plenum Press; 1999: 389–405.
   Google Scholar
• Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996; 32A: 2474–84.
   PubMed Web of Science ®Google Scholar
• Weidner N, Folkman J. Tumoral vascularity as a prognostic factor in cancer. Important Adv Oncol 1996;167–90.
   PubMedGoogle Scholar
• Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication. Semin Diagn Pathol 1993; 10: 302–13.
   PubMed Web of Science ®Google Scholar
• Ellis LM, Walker RA, Gasparini G. Is determination of angiogenic activity in human tumours clinically useful? Eur J Cancer 1998; 34: 609–18.
   Google Scholar
• Vartanian RK, Weidner N. Endothelial cell prolifera-tion in prostatic carcinoma and prostatic hyperplasia: correlation with Gleason's score, microvessel density, and epithelial cell proliferation. Lab Invest 1995; 73: 844–50.
   PubMed Web of Science ®Google Scholar
• Vartanian RK, Weidner N. Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. Am J Pathol 1994; 144: 1188–94.
   PubMed Web of Science ®Google Scholar
• Fox SB, Gatter KC, Bicknell R, Going JJ, Stanton P, Cooke TG et al. Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Res 1993; 53: 4161–63.
   PubMed Web of Science ®Google Scholar
• Aotake T, Lu CD, Chiba Y, Muraoka R, Tanigawa N. Changes of angiogenesis and tumor cell apoptosis during colorectal carcinogenesis. Clin Cancer Res 1999; 5: 135–42.
   Google Scholar
• Ikeguchi M, Cai J, Yamane N, Maeta M, Kaibara N. Clinical significance of spontaneous apoptosis in advanced gastric adenocarcinoma. Cancer 1999; 85: 2329–35.
   Google Scholar
• Nguyen M. Angiogenic factors as tumor markers. Invest New Drugs 1997; 15: 29–37.
   PubMed Web of Science ®Google Scholar
• Li WW. Tumor angiogenesis: molecular pathology, therapeutic targeting, and imaging. Acad Radiol 2000; 7: 800–11.
   PubMed Web of Science ®Google Scholar
• Brasch RC, Li KC, Husband JE, Keogan MT, Neeman M, Padhani AR, et al. In vivo monitoring of tumor angiogenesis with MR imaging. Acad Radiol 2000; 7: 812–23.
   PubMed Web of Science ®Google Scholar
• Neeman M, Provenzale IM, Dewhirst MW. Magnetic resonance imaging applications in the evaluation of tumor angiogenesis. Semin Radiat Oncol 2001; 11: 70–
   Google Scholar
• Boehm-Viswanathan T. Is angiogenesis inhibition the Holy Grail of cancer therapy? Curr Opin Oncol 2000; 12: 89–94.
   PubMed Web of Science ®Google Scholar
• Bloemendal HJ, Logtenberg T, Voest EE. New strategies in anti-vascular cancer therapy. Eur J Clin Invest 1999; 29: 802–09.
   Google Scholar
• Augustin HG. Antiangiogenic tumour therapy: will it work? Trends Pharmacol Sci 1998; 19: 216–22.
   PubMed Web of Science ®Google Scholar
• Deering RE, Bigler SA, Brown M, Brawer MK. Microvascularity in benign prostatic hyperplasia. Pros-tate 1995; 26: 111–15.
   PubMed Web of Science ®Google Scholar
• Jackson MW, Bentel JM, Tilley WD. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 1997; 157: 2323–28.
   Google Scholar
• Hahn D, Simak R, Steiner GE, Handisurya A, Susani M, Marberger M. Expression of the VEGF-receptor Flt-1 in benign, premalignant, and malignant prostate tissues. J Urol 2000; 164: 506–10.
   PubMed Web of Science ®Google Scholar
• Montironi R, Galluzzi C, Diamanti L, Taborro R, Scarpelli M, Pisani E. Prostatic Intra-epithelial Neo-plasia Qualitative and quantitative analyses of the blood capillary architecture on this tissue sections. Path Res Pract 1993; 189: 542–48.
   PubMed Web of Science ®Google Scholar
• Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA. Predictors of pathologic stage in prostatic carcino-ma. The role of neovascularity. Cancer 1994; 73: 678–87.
   Google Scholar
• Waters DJ, Hayden DW, Bell FW, Klausner JS, Qian J, Bostwick DG. Prostatic intraepithelial neoplasia in dogs with spontaneous prostate cancer. Prostate 1997; 30: 92–97.
   PubMed Web of Science ®Google Scholar
• Mazzucchelli R, Montironi R, Santinelli A, Lucarini G, Pugnaloni A, Biagini G. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate 2000; 45: 72–79.
   PubMed Web of Science ®Google Scholar
• Montironi R, Diamanti L, Thompson D, Bartels HG, Bartels PH. Analysis of the capillary architecture in the precursors of prostate cancer: recent findings and new concepts. Eur Urol 1996; 30: 191–200.
   Google Scholar
• Newling D. PIN I-III: when should we interfere? Eur Urol 1999; 35: 504–07.
   PubMed Web of Science ®Google Scholar
• Bostwick DG, Foster CS. Predictive factors in prostate cancer: current concepts from the 1999 College of American Pathologists Conference on Solid Tumor Prognostic Factors and the 1999 World Health Organization Second International Consultation on Prostate Cancer. Semin Urol Oncol 1999; 17: 222–72.
   PubMedGoogle Scholar
• Gerber HP, Hillan KJ, Ryan AM, Kowalski J, Keller GA, Rangell L, et al. VEGF is required for growth and survival in neonatal mice. Development 1999; 126: 1149–59.
   PubMed Web of Science ®Google Scholar
• Modlich U, Kaup FJ, Augustin HG. Cyclic angiogen-esis and blood vessel regression in the ovary: blood vessel regression during luteolysis involves endothelial cell detachment and vessel occlusion. Lab Invest 1996; 74: 771–80.
   Google Scholar
• Tatarczuch L, Philip C, Lee CS. Involution of the sheep mammary gland. J Anat 1997; 190: 405–16.
   Google Scholar
• Honma T, Hamasaki T. Ultrastructure of blood vessel regression in involution of foreign-body granuloma. J Submicrosc Cytol Pathol 1998; 30: 31–44.
   PubMedGoogle Scholar
• Walker NI, Bennett RE, Kerr if. Cell death by apoptosis during involution of the lactating breast in mice and rats. Am J Anat 1989; 185: 19–32.
   Google Scholar
• Buttyan R, Shabsigh A, Perlman H, Colombel M. Regulation of apoptosis in the prostate gland by androgenic steroids. Trends Endocrinol Metab 1999; 10: 47–54.
   PubMed Web of Science ®Google Scholar
• Connor J, Sawczuk IS, Benson MC, Tomashefsky P, O'Toole KM, Olsson CA, et al. Calcium channel antagonists delay regression of androgen-dependent tissues and suppress gene activity associated with cell death. Prostate 1988; 13: 119–30.
   Google Scholar
• Kyprianou N, English HF, Isaacs JT. Activation of a Ca2+-Mg2+-dependent endonuclease as an early event in castration-induced prostatic cell death. Prostate 1988; 13: 103–17.
   Google Scholar
• Prins GS, Birch L, Greene GL. Androgen receptor localization in different cell types of the adult rat prostate. Endocrinology 1991; 129: 3187–99.
   Google Scholar
• Pelletier G, Labrie C, Labrie F. Localization of oestrogen receptor alpha, oestrogen receptor beta and androgen receptors in the rat reproductive organs. J Endocrinol 2000; 165: 359–70.
   Google Scholar
• Sar M, Lubahn DB, French FS, Wilson EM. Immuno-histochemical localization of the androgen receptor in rat and human tissues. Endocrinology 1990; 127: 3180–6.
   PubMed Web of Science ®Google Scholar
• El Alfy M, Luu-The V, Huang XF, Berger L, Labrie F, Pelletier G. Localization of type 5 17beta-hydroxyster-oid dehydrogenase, 3beta- hydroxy steroid dehydrogen-ase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endo-crinology 1999; 140: 1481–91.
   PubMed Web of Science ®Google Scholar
• Padhani AR, Gapinski CJ, Macvicar DA, Parker GJ, Suckling J, Revell PB, et al. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol 2000; 55: 99–109.
   PubMed Web of Science ®Google Scholar
• Campbell CL, Savarese DM, Quesenberry PJ, Savarese TM. Expression of multiple angiogenic cytokines in cultured normal human prostate epithelial cells: pre-dominance of vascular endothelial growth factor. Int J Cancer 1999; 80: 868–74.
   PubMed Web of Science ®Google Scholar
• Haggstrom S, Wikstrom P, Bergh A, Damber JE. Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration. Prostate 1998; 36: 71–9.
   PubMed Web of Science ®Google Scholar
• Burchardt M, Burchardt T, Chen MW, Hayek OR, Knight C, Shabsigh A, et al. Vascular endothelial growth factor-A expression in the rat ventral prostate gland and the early effects of castration. Prostate 2000; 43: 184–94.
   PubMed Web of Science ®Google Scholar
• Sordello S, Bertrand N, Plouet J. Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochem Biophys Res Commun 1998; 251: 287–90.
   PubMed Web of Science ®Google Scholar
• Brown LF, Yeo KT, Berse B, Morgentaler A, Dvorak HF, Rosen S. Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen. J Urol 1995; 154: 576–79.
   PubMed Web of Science ®Google Scholar
• Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 1997; 157: 2329–33.
   PubMed Web of Science ®Google Scholar
• Kirschenbaum A, Klausner AP, Lee R, Unger P, Yao S, Liu XH, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology 2000; 56: 671–6.
   PubMed Web of Science ®Google Scholar
• Kirschenbaum A, Liotta DR, Yao S, Liu XH, Klausner AP, Unger P, et al. Immunohistochemical localization of cyclooxygenase-1 and cyclooxygenase-2 in the human fetal and adult male reproductive tracts. J Clin Endocrinol Metab 2000; 85: 3436–41.
   PubMed Web of Science ®Google Scholar
• Nie D, Tang K, Szekeres K, Li L, Honn KV. Eicosanoid regulation of angiogenesis in human prostate carcinoma and its therapeutic implications. Ann N Y Acad Sci 2000; 905: 165–76.
   Google Scholar
• Ferrer FA, Miller LJ, Lindquist R, Kowalczyk P, Laudone VP, Albertsen PC, et al. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 1999; 54: 567–572.
   PubMed Web of Science ®Google Scholar
• Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, et al. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 1998; 51: 1617.
   Web of Science ®Google Scholar
• Harper ME, Glynne-Jones E, Goddard L, Thurston VJ, Griffiths K. Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. Br J Cancer 1996; 74: 910–16.
   PubMed Web of Science ®Google Scholar
• Bone M, Nerstrom B, Overgaard J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine- differentiated tumor cells, and out-come in prostate cancer patients subjected to watchful waiting. Clin Cancer Res 2000; 6: 1882–90.
   Google Scholar
• Haggstrom S, Bergh A, Damber JE. Vascular endothe-lial growth factor content in metastasizing and non-metastasizing dunning prostatic adenocarcinoma. Pros-tate 2000; 45: 42–50.
   Google Scholar
• Chen HJ, Treweeke AT, YQ, West DC, Toh CH. Angiogenically active vascular endothelial growth Ke factor is over- expressed in malignant human and rat prostate carcinoma cells. Br J Cancer 2000; 82: 1694–1701.
   Google Scholar
• Kuniyasu H, Troncoso P, Johnston D, Bucana CD, Tahara E, Fidler IJ, et al. Relative expression of type IV collagenae, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prosta-tectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res 2000; 6: 2295–2308.
   PubMed Web of Science ®Google Scholar
• Borgstrom P, Bourdon MA, HiIlan KJ, Sriramarao P, Ferrara N. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogen-esis and growth of human prostate carcinoma micro tumors in vivo. Prostate 1998; 35: 1–10.
   Google Scholar
• Melnyk O, Zimmerman M, Kim KJ, Shuman M. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J Urol 1999; 161: 960–3.
   PubMed Web of Science ®Google Scholar
• Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen JO, Hennequin LF, et al. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 2000; 60: 970–5.
   PubMed Web of Science ®Google Scholar
• Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, et al. 5U5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/ KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59: 99–106.
   PubMed Web of Science ®Google Scholar
• Strohmeyer D, Rossing C, Strauss F, Bauerfeind A, Kaufmann O, Loening S. Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer. Prostate 2000; 42: 26–33.
   PubMed Web of Science ®Google Scholar
• Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, Jaattela M, et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 2001; 61: 1786–90.
   Google Scholar
• Stearns ME, Garcia FU, Fudge K, Rhim J, Wang M. Role of interleukin 10 and transforming growth factor betal in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. Clin Cancer Res 1999; 5:711–20.
   Google Scholar
• Wikstrom P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A. Transforming growth factor betal is asso-ciated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 1998; 37: 19–29.
   Google Scholar
• Dow JK, deVere White RW. Fibroblast growth factor 2: its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and onco-genic functions. Urology 2000; 55: 800–06.
   PubMed Web of Science ®Google Scholar
• Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, et al. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 2000; 6: 2104–19.
   PubMed Web of Science ®Google Scholar
• Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000; 164: 820–5.
   PubMed Web of Science ®Google Scholar
• Farnsworth WE. Prostate stroma: physiology. Prostate 1999; 38: 60–72.
   PubMed Web of Science ®Google Scholar
• Grobholz R, Bohrer MH, Siegsmund M, Junemann KP, Bleyl U, Woenckhaus M. Correlation between neo- vascularisation and neuroendocrine differentiation in prostatic carcinoma. Pathol Res Pract 2000; 196: 277–84.
   PubMed Web of Science ®Google Scholar
• Lissbrant IF, Stattin P, Wikstrom P, Damber JE, Egevad L, Bergh A. Tumor associated macrophages in human prostate cancer: relation to clinicopathological vari- ables and survival. Int J Oncol 2000; 17: 445–51.
   PubMed Web of Science ®Google Scholar
• Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC. Reduced infiltration of tumor-asso-ciated macrophages in human prostate cancer: associa-tion with cancer progression. Cancer Res 2000; 60: 5857–61.
   PubMed Web of Science ®Google Scholar
• Gately S, Twardowski P, Stack MS, Patrick M, Boggio L, Cundiff DL, et al. Human prostate carcinoma cells express enzymatic activity that converts human plas-minogen to the angiogenesis inhibitor, angiostatin. Cancer Res 1996; 56: 4887–90.
   PubMed Web of Science ®Google Scholar
• Westphal JR, Van't Hullenaar R, Geurts-Moespot A, Sweep FC, Verheijen JH, Bussemakers MM, et al. Angiostatin generation by human tumor cell lines: involvement of plasminogen activators. Int J Cancer 2000; 86: 760–7.
   Google Scholar
• Chen C, Parangi S, Tolentino MJ, Folkman J. A strategy to discover circulating angiogenesis inhibitors gener-ated by human tumors. Cancer Res 1995; 55: 4230–33.
   PubMed Web of Science ®Google Scholar
• Hartford AC, Gohongi T, Fukumura D, Jain RK. Irradiation of a primary tumor, unlike surgical removal, enhances angiogenesis suppression at a distal site: potential role of host-tumor interaction. Cancer Res 2000; 60: 2128–31.
   PubMed Web of Science ®Google Scholar
• Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogen-esis inhibitor angiostatin. Proc Natl Acad Sci USA 1997; 94: 10868–72.
   PubMed Web of Science ®Google Scholar
• Mehta R, Kyshtoobayeva A, Kurosaki T, Small EJ, Kim H, Stroup R, et al. Independent association of angiogenesis index with outcome in prostate cancer. Chin Cancer Res 2001; 7: 81–8.
   Web of Science ®Google Scholar
• Jin RJ, Kwak C, Lee SG, Lee CH, Park MS, Lee E, et al. The application of an antiangiogenic gene (thrombos-pondin-1) in the treatment of human prostate cancer xenografts. Cancer Gene Ther 2000; 7: 1537–42.
   PubMed Web of Science ®Google Scholar
• Fortier AH, Nelson BJ, Grella DK, Holaday JW. Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst 1999; 91: 1635–40.
   PubMed Web of Science ®Google Scholar
• Heidtmann HH, Nettelbeck DM, Mingels A, Jager R, Welker HG, Kontermann RE. Generation of angiosta-tin-like fragments from plasminogen by prostate-specific antigen. Br J Cancer 1999; 81: 1269–73.
   PubMed Web of Science ®Google Scholar
• Bone M, Offersen BV, Nerstrom B, Overgaard J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 1998; 78: 940–4.
   PubMed Web of Science ®Google Scholar
• Offersen BV, Bone M, Overgaard J. Immunohisto-chemical determination of tumor angiogenesis measured by the maximal microvessel density in human prostate cancer. APMIS 1998; 106: 463–9.
   Google Scholar
• Furusato M, Wakui S, Sasaki H, Ito K, Ushigome S. Tumour angiogenesis in latent prostatic carcinoma. Br J Cancer 1994; 70: 1244–6.
   Google Scholar
• Bettencourt MC, Bauer JJ, Sesterhenn IA, Connelly RR, Moul JW. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol 1998; 160: 459–65.
   Google Scholar
• Matsushima H, Goto T, Hosaka Y, Kitamura T, Kawabe K. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation. Cancer 1999; 85: 1822–7.
   Google Scholar
• Mydlo JH, Kral JG, Volpe M, Axotis C, Macchia RJ, Pertschuk LP. An analysis of microvessel density, androgen receptor, p53 and HER- 2/neu expression and Gleason score in prostate cancer. Preliminary results and therapeutic implications. Eur Urol 1998; 34: 426–32.
   Google Scholar
• de la TA, Katz AE, Bagiella E, Buttyan R, Sharir S, Ols son CA, et al. Microvessel density as a predictor of PSA recurrence after radical prostatectomy. A com-parison of CD34 and CD31. Am J Clin Pathol 2000; 113: 555–62.
   Google Scholar
• Halvorsen OJ, Haukaas S, Hoisaeter PA, Akslen LA. Independent prognostic importance of microvessel density in clinically localized prostate cancer. Anti-cancer Res 2000; 20: 3791–9.
   PubMed Web of Science ®Google Scholar
• Gettman MT, PaceIli A, Slezak J, Bergstralh EJ, Blute M, Zincke H, et al. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma. Urology 1999; 54: 479–85.
   PubMed Web of Science ®Google Scholar
• Gettman MT, Bergstralh EJ, Blute M, Zincke H, Bostwick DG. Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: lack of significance for microvessel density analysis. Urology 1998; 51: 79–85.
   Google Scholar
• Lissbrandt IF, Stattin P, Damber JE, Bergh A. Vascular density is a predictor of cancer-specific survival in prostatic carcinoma. Prostate 1997; 33: 38–45.
   PubMed Web of Science ®Google Scholar
• Silberman MA, Partin AW, Veltri RW, Epstein JI. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 1997; 79: 772–9.
   PubMed Web of Science ®Google Scholar
• Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000; 60: 1388–93.
   PubMed Web of Science ®Google Scholar
• Gasparini G, Brooks PC, Biganzoli E, Vermeulen PB, Bonoldi E, Dirix LY, et al. Vascular integrin alpha(v)-beta3: a new prognostic indicator in breast cancer. Chin Cancer Res 1998; 4: 2625–34.
   Web of Science ®Google Scholar
• Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, Wang JM, et al. Breast carcinoma: vascular density deter-mined using CD105 antibody correlates with tumor prognosis. Cancer Res 1999; 59: 856–61.
   PubMed Web of Science ®Google Scholar
• Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metas-tasis in invasive prostate carcinoma. Am J Pathol 1993; 143: 401–09.
   Google Scholar
• Moul JW. Angiogenesis, p53, bc1-2 and Ki-67 in the progression of prostate cancer after radical prostatec-tomy. Eur Urol 1999; 35: 399–407.
   PubMed Web of Science ®Google Scholar
• Yorukoglu K, Sagol O, Ozkara E, Mungan U, Kirkali Z. Comparison of microvascularization in diagnostic needle biopsies and radical prostatectomies in prostate carcinoma. Eur Urol 1999; 35: 109–12.
   Google Scholar
• Rogatsch, H, Hittmair A, Reissigl A, MikuzG, Feich-tinger H. Microvessel density in core biopsies of prostatic adenocarcinoma: a stage predictor? J Pathol 1997; 182: 205–10.
   Google Scholar
• Ismail M, Petersen RO, Alexander AA, Newschaffer C, Gomella LG. Color Doppler imaging in predicting the biologic behavior of prostate cancer: correlation with disease-free survival. Urology 1997; 50: 906–12.
   Google Scholar
• Salven P, Manpaa H, Orpana A, Alitalo K, Joensuu H. Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res 1997; 3: 647–51.
   Google Scholar
• Jones A, Fujiyama C, Turner K, Fuggle S, Cranston D, Bicknell R, et al. Elevated serum vascular endothelial growth factor in patients with hormone-escaped pros-tate cancer. BJU Int 2000; 85: 276–80.
   PubMed Web of Science ®Google Scholar
• Duque JL, Loughlin KR, Adam R1\4, Kantoff PW, Zurakowski D, Freeman MR. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999; 54: 523–7.
   Google Scholar
• Walsh K, Sherwood RA, Dew TK, Mulvin D. Angiogenic peptides in prostatic disease. BJU Int 1999; 84: 1081–3.
   PubMed Web of Science ®Google Scholar
• Turner K, Jones A. Vascular endothelial growth factor in prostate cancer. Urology 2000; 56: 183.
   PubMed Web of Science ®Google Scholar
• Bok RA, Halabi S, Fei DT, Rodriquez CR, Hayes DF, Vogelzang NJ, et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res 2001; 61: 2533–6.
   PubMed Web of Science ®Google Scholar
• Rak J, Filmus J, Kerbel RS. Reciprocal paracrine interactions between tumour cells and endothelial cells: the `angiogenesis progression' hypothesis. Eur J Cancer 1996; 32A: 2438–50.
   Google Scholar
• Yoshiji H, Harris SR, Thorgeirsson UP. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res 1997; 57: 3924–8.
   Google Scholar
• Fuhrmann-Benzakein E, Ma MN, Rubbia-Brandt L, Mentha G, Ruefenacht D, Sappino AP, et al. Elevated levels of angiogenic cytokines in the plasma of cancer patients. Int J Cancer 2000; 85: 40–45.
   PubMedGoogle Scholar
• All IU, Senger DR, Smith LE. Angiogenesis as a potential biomarker in prostate cancer chemoprevention trials. Urology 2001; 57: 143–7.
   Google Scholar
• O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277–85.
   PubMed Web of Science ®Google Scholar
• Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999; 284: 808–12.
   Google Scholar
• Folkman J. The logic of anti-angiogenic gene therapy. In: Friedmann T, editor. The development of human gene therapy. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press, 1999: 527–43.
   Google Scholar
• National Cancer Institute database. http://cancertrials. nci.nih.govinews/angio/table/html.
   Google Scholar
• Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999; 59: 3374–8.
   PubMed Web of Science ®Google Scholar
• Hansen-Algenstaedt N, Stoll BR, Padera TP, Dolmans DE, Hicklin DJ, Fukumura D, et al. Tumor oxygenation in hormone-dependent tumors during vascular endothe-lial growth factor receptor-2 blockade, hormone abla-tion, and chemotherapy. Cancer Res 2000; 60: 4556–60.
   Google Scholar
• Zietman AL, Prince EA, Nakfoor BM, Park JJ. Androgen deprivation and radiation therapy: sequen-cing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys 1997; 38: 1067–70.
   PubMed Web of Science ®Google Scholar
• Hartley-Asp B, Vukanovic J, Joseph TB, Strandgarden K, Polacek J, Isaacs JT. Anti-angiogenic treatment with linomide as adjuvant to surgical castration in experi-mental prostate cancer. J Urol 1997; 158: 902–07.
   Google Scholar